NASOPHARYNGEAL CANCER (NPC)

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer

Retrieved on: 
Monday, August 23, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Nasopharyngeal Cancer (NPC), Tislelizumab, the Tislelizumab Clinical Program, BeiGene, NASOPHARYNGEAL CANCER (NPC), TISLELIZUMAB, THE TISLELIZUMAB CLINICAL PROGRAM, BEIGENE

The safety profile of tislelizumab was consistent with its known risks, with no new safety signals identified with the addition of chemotherapy.

Key Points: 
  • The safety profile of tislelizumab was consistent with its known risks, with no new safety signals identified with the addition of chemotherapy.
  • BeiGene expects to present results from the RATIONALE 309 trial at an upcoming medical conference.
  • BeiGene has initiated or completed 17 potentially registration-enabling clinical trials in China and globally, including 13 Phase 3 trials and four pivotal Phase 2 trials.
  • In January 2021, BeiGene and Novartis entered into a collaboration and license agreement granting Novartis rights to develop, manufacture, and commercialize tislelizumab in North America, Europe, and Japan.

BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Retrieved on: 
Friday, May 21, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Infectious causes of cancer, Clinical endpoint, Clinical research, Nasopharyngeal carcinoma, Health, Cancer, Medical research, Nasopharyngeal Cancer (NPC), Tislelizumab, the Tislelizumab Clinical Program, BeiGene, NASOPHARYNGEAL CANCER (NPC), TISLELIZUMAB, THE TISLELIZUMAB CLINICAL PROGRAM, BEIGENE

In the trial results, tislelizumab in combination with chemotherapy demonstrated a statistically significant improvement in PFS in the intention-to-treat (ITT) population when compared to chemotherapy alone, as assessed by an independent review committee (IRC).

Key Points: 
  • In the trial results, tislelizumab in combination with chemotherapy demonstrated a statistically significant improvement in PFS in the intention-to-treat (ITT) population when compared to chemotherapy alone, as assessed by an independent review committee (IRC).
  • Key secondary endpoints include overall survival (OS), IRC-assessed objective response rate (ORR) and duration of response (DoR), and investigator-assessed PFS.
  • Greater intake of fruit and vegetables is associated with lower risk of nasopharyngeal carcinoma in Chinese adults: A case-control study.
  • Metastatic Patterns and Prognosis of de novo Metastatic Nasopharyngeal Carcinoma in the United States.